

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/248478 A1

- (51) **International Patent Classification:**
A61P 35/00 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/EP2022/064061
- (22) **International Filing Date:**
24 May 2022 (24.05.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/192,217 24 May 2021 (24.05.2021) US
- (71) **Applicant: ASTRAZENECA AB** [SE/SE]; SE-151 85, Södertälje (SE).
- (72) **Inventors: JARKOWSKI, III, Anthony;** c/o AstraZeneca Pharmaceuticals, LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **DENNIS, Phillip;** c/o AstraZeneca Pharmaceuticals, LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **TRANI, Leo;** c/o AstraZeneca Pharmaceuticals, LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **NEWTON, Michael;** c/o AstraZeneca Pharmaceuticals, LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SHIRE, Norah;** c/o AstraZeneca Pharmaceuticals, LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).
- (74) **Agent: MACLEAN, Martin Robert;** Mathys & Squire, The Shard, 32 London Bridge Street, London SE1 9SG (GB).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER




FIGURE 1

(57) **Abstract:** Disclosed are methods for treating locally advanced (Stage III), unresectable non-small- cell lung cancer (NSCLC) with an antibody that inhibits PD-1/PD-L1 activity concurrently with chemoradiation therapy (cCRT).

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*